First oligonucleotide in U.S. clinical trials for CMV retinitis.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy*; D017277:Drug Approval; D005602:France; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D016376:Oligonucleotides, Antisense